1. Berberine associated to SGLT2i Dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to Trastuzumab through reduction of AGEs and IL-6 and induction of pAMPK. (3rd October 2022) Authors: Maurea, N; Buccolo, S; Iovine, M; Maurea, C; Paccone, A; Quagliariello, V Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. C49 SACUBITRIL–VALSARTAN IMPROVES LONGITUDINAL STRAIN AND EJECTION FRACTION IN MICE TREATED WITH DOXORUBICIN THROUGH NLRP3, MYD88 PATHWAYS RESULTING IN A REDUCTION OF MYOCARDIAL IL–1Β, IL–6, TNF–Α, G–CSF AND GM–CSF LEVELS. (18th May 2022) Authors: Quagliariello, V; Iovine, M; Buccolo, S; Paccone, A; Maurea, N Journal: European heart journal supplements Issue: Volume 24(2022)Supplement C Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evolocumab, a PCSK9 inhibitor, co-incubated with doxorubicin and trastuzumab reduces death of cardiomyocytes through reduction of MyD88-NLRP3-NF-kB-mTORC1. (14th October 2021) Authors: Quagliariello, V; Bonelli, A; Paccone, A; Buccolo, S; Iovine, M; Conforti, G; Botti, G; Maurea, N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Ipilimumab and Nivolumab exertes cardiotoxic and pro-fibrotic effects in mice through the overexpression of NLRP3 inflammasome, chemokines and leukotrienes. (14th October 2021) Authors: Quagliariello, V; Passariello, M; Rea, D; Barbieri, A; Buccolo, S; Iovine, M; Bonelli, A; Caronna, A; Botti, G; De Lorenzo, C; Maurea, N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Oxidized Low-Density Lipoproteins increases nivolumab-induced cardiotoxicity through TLR4/NF-KB and NLRP3 pathways. (14th October 2021) Authors: Quagliariello, V; Bonelli, A; Paccone, A; Buccolo, S; Iovine, M; Botti, G; Maurea, N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P131 LOW DOSES OF ADVANCED GLYCATION END–PRODUCTS AND FRUCTOSILATION PRODUCTS PROMOTES PREMATURE CELL DEATH OF HUMAN CARDIAC CELLS EXPOSED TO DOXORUBICIN VIA ACTIVATION OF NLRP3, MYD88 AND P53 DOWNREGULATION. (18th May 2022) Authors: Quagliariello, V; Paccone, A; Iovine, M; Buccolo, S; Maurea, N Journal: European heart journal supplements Issue: Volume 24(2022)Supplement C Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P142 PALMITOYLETHANOLAMIDE (PEA) REDUCES INFLAMMATION IN HUMAN CARDIOMYOCYTES AND VASCULAR ENDOTHELIAL CELLS EXPOSED TO DOXORUBICIN AND ANTI–HER2 MONOCLONAL ANTIBODY THROUGH PPAR–Α AND NLRP3–RELATED PATHWAYS. (18th May 2022) Authors: Quagliariello, V; Buccolo, S; Iovine, M; Paccone, A; Maurea, N Journal: European heart journal supplements Issue: Volume 24(2022)Supplement C Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P221 DAPAGLIFLOZIN ASSOCIATED TO SACUBITRIL/VALSARTAN EXERTS ADDITIVE CARDIOPROTECTION IN HUMAN CARDIOMYOCYTES EXPOSED TO DOXORUBICIN AND TRASTUZUMAB THROUGH MYD88, NLRP3 MEDIATED PATHWAYS AND IMPROVEMENT OF MYTOGENESIS. (18th May 2022) Authors: Quagliariello, V; Iovine, M; Buccolo, S; Maurea, N Journal: European heart journal supplements Issue: Volume 24(2022)Supplement C Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue. (3rd October 2022) Authors: Maurea, N; De Lorenzo, C; Passariello, M; Iovine, M; Buccolo, S; Di Mauro, A; Cipullo, C; Paccone, A; Maurea, F; Caronna, A; Quagliariello, V Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Sacubitril-valsartan activates pAMPK and reduces NLRP3, MyD88, cytokines/growth factors and DAMPs in doxorubicin-treated mice improving longitudinal strain and ejection fraction. (3rd October 2022) Authors: Maurea, N; Buccolo, S; Iovine, M; Paccone, A; Luciano, A; Barbieri, A; Palma, G; Maurea, C; Quagliariello, V Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗